Patent Expiry of Biologics to Provide Potential Growth for Biosimilars
This research service presents an overview of the South Korean biosimilars
market and analyzes the opportunities that lay ahead for different
stakeholders in the development, manufacturing, and commercialization of
biosimilars. This service divides the market into therapeutic proteins and
monoclonal antibodies. Further, it aims to present an overview of the global
biosimilars market and covers impending patent expiries for biologics,
regulatory guidelines, pipeline data, and important participants in the
market. Moreover, key market challenges, drivers, and restraints are
discussed. The forecast period extends through 2015, with a base year of 2010.
Key Questions This Study Will Answer
What are the key factors driving the market, and what are the barriers
that need to be resolved?
What is the current scenario for the South Korean biosmilars market, and
how long will this scenario last?
What are the major market segments, and what are their important trends?
Who are the key market participants involved, and where do they stand?
What is the future of the biosimilars market in South Korea, and what
should market participants do to succeed?
Table of Contents
Table of Contents
1. Executive Summary
2. Market Overview
3. Total Market
External Challenges: Drivers and Restraints
Forecast and Trends
4. Regulatory Developments
5. Competitors
6. Company Profiles
7. The Last Word (Conclusions and Implications)
8. Appendix
9. Decision Support Database
Opportunity Analysis for Biosimilars - South Korea published by Frost & Sullivan in September 5, 2012. This report price starts from US $ 6500.
